Revlimid, Imnovid combos receive EU approval

The European Commission has approved two of Celgene’s combination regimens involving Revlimid (lenalidomide) and Imnovid (pomalidomide). The first, Revlimid in combination with bortezomib and dexamethasone (RVd) is for the indication of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Read more...

;